For research use only · Not for human or animal consumption

Third-party tested

Triple-Action Metabolic Compound

GLP-3 RT

LY3437943

GLP-3 CAS 2381089-83-2

A 39-amino acid triple agonist peptide targeting GIP, GLP-1, and glucagon receptors, studied for metabolic regulation and body composition in clinical research.

$70.00$7.00 / mg

Strength

Availability: 24 in stock

Fast U.S. shippingFree on orders over $200

Third-party testedIndependent lab, every batch

Purity documentedHPLC + mass spec

Secure checkoutVenmo · Cash App · Zelle

01Research snapshot

GLP-3 RT, by the numbers.

Structural and laboratory facts that define this compound. For laboratory research use only.

Receptor targets

GLP-1R · GIPR · GCGR

Amino acid residues

GIP-based peptide backbone

Molecular weight

g/mol · C221H342N46O68

~0d

Reported half-life

Published pharmacokinetic data

02Molecular structure

The GLP-3 RT molecule

A schematic atomic representation shown next to the compound's molecular data. The figure is illustrative, not a measured conformation.

CHNOS

Molecular formula

C₂₂₁H₃₄₂N₄₆O₆₈

Mol. weight4731.3 g/mol

Sequence length—

CAS2381089-83-2

Physical formLyophilized powder

Purity99%+ HPLC

Use classResearch only

03Mechanism of action

How it is studied.

First-in-class triple hormone receptor agonist (LY3437943) targeting three distinct metabolic pathways simultaneously

GLP-1R GLP-1 Receptor Agonism

Activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon release, delay gastric emptying, and engage central appetite regulation pathways in the hypothalamus. This is the same pathway targeted by semaglutide and liraglutide.

Glucose-dependent insulin secretion
Delayed gastric emptying
Central appetite suppression

GIPR GIP Receptor Agonism

Co-agonism at GIP receptors potentiates the metabolic effects of GLP-1 signaling, enhances lipid metabolism, and modulates adipose tissue remodeling. This dual GLP-1/GIP mechanism is shared with tirzepatide, but GLP-3 RT adds a third target.

Synergistic insulin potentiation
Lipid metabolism enhancement
Adipose tissue signaling

GCGR Glucagon Receptor Agonism

The unique third target — glucagon receptor activation increases hepatic energy expenditure, promotes fatty acid oxidation, and drives thermogenesis. This differentiates GLP-3 RT from all dual agonists and may account for its superior weight reduction in trials.

Hepatic energy expenditure increase
Enhanced fatty acid oxidation
Thermogenic pathway activation

Research pathway map

The primary pathways GLP-3 RT is investigated against in laboratory models.

Illustrative schematic based on published in-vitro and preclinical observations. Research use only.

04Specifications

Compound details.

Chemical nameLY3437943

SynonymsLY3437943, GLP-3

FormulaC221H342N46O68

Molecular weight4731.3 g/mol

CAS number2381089-83-2

FormLyophilized powder

DocumentationThird-party COA, per batch

Storage & handling

Supplied as a lyophilized powder. Store the sealed vial refrigerated at 2–8°C, protected from light and moisture; −20°C for long-term storage. Keep reconstituted material refrigerated.

FOR RESEARCH USE ONLYNot for human or animal consumption. Intended strictly for qualified researchers performing in-vitro or analytical laboratory work. No medical, diagnostic or therapeutic claims are made.

Cell Metab · 2022LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept

Discovery, receptor pharmacology and early characterization of LY3437943.

Coskun T et al., 2022 · PubMed ↗

N Engl J Med · 2023Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial

Phase 2 clinical study of LY3437943.

Jastreboff AM et al., 2023 · PubMed ↗

Lancet · 2023Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial

Phase 2 clinical study of LY3437943.

Rosenstock J et al., 2023 · PubMed ↗